NCT04606472View on ClinicalTrials.gov

A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

November 10, 2020

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Solid Tumor
Interventions
DRUG

SI-B003

Administration by intravenous infusion.

Trial Locations (8)

100142

Beijing Cancer Hospital, Beijing

450008

Henan Cancer Hospital, Zhengzhou

Unknown

Chongqing University Cancer Hospital, Chongqing

The First Affiliated Hospital of Xiamen University, Xiamen

Hubei Cancer Hospital, Wuhan

Union Hospital Tongji Medical College, Huazhong University of Science and Technology, Wuhan

Shanghai Central Hospital, Shanghai

West China Hospital, Sichuan University, Chengdu

All Listed Sponsors
collaborator

SystImmune Inc.

INDUSTRY

lead

Sichuan Baili Pharmaceutical Co., Ltd.

INDUSTRY

NCT04606472 - A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter